27 May 2016 - The U.S. FDA today approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated prostate specific antigen (PSA) levels following prior treatment.

Prostate cancer is the second leading cause of death from cancer in U.S. men. In patients with suspected cancer recurrence after primary treatment, accurate staging is an important objective in improving management and outcomes.

“Imaging tests are not able to determine the location of the recurrent prostate cancer when the PSA is at very low levels,” said Libero Marzella, M.D., Ph.D., director of the Division of Medical Imaging Products in the FDA’s Center for Drug Evaluation and Research. “Axumin is shown to provide another accurate imaging approach for these patients.”

Axumin is marketed by Blue Earth Diagnostics, Ltd., Oxford, United Kingdom.

For more details, go to: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm503920.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery